阿拉伯甘露聚糖-CRM197偶联物的合成与免疫原性。
Synthesis and immunogenicity of the arabinomannan-CRM197 conjugate.
作者信息
Chang Yunsong, Meng Xin, Li Yaxin, Liang Jianmei, Li Tingshen, Meng Demei, Zhu Tao, Yu Peng
机构信息
Key Laboratory of Industrial Microbiology , Ministry of Education , College of Biotechnology , Tianjin University of Science and Technology , Tianjin 300457 , PR China . Email:
State Key Laboratory of Food Nutrition and Safety , College of Food Engineering and Biotechnology , Tianjin University of Science & Technology , Tianjin , 300457 , PR China.
出版信息
Medchemcomm. 2019 Apr 2;10(4):543-553. doi: 10.1039/c8md00546j. eCollection 2019 Apr 1.
Lipoarabinomannan (LAM) is a major structural surface component of . This study describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies. Arabinomannan (AM) dodecasaccharide has been efficiently synthesized and covalently conjugated to carrier proteins, including cross reactive mutant (CRM197) diphtheria toxoid and bovine serum albumin (BSA) for novel neoglycoconjugates, creating a potent T-dependent conjugate vaccine. Preliminary mice immunization studies on the neoglycoconjugate revealed that it could give rise to a strong IgG antibody titer in mice at 4.0 μg dose with an aluminum phosphate adjuvant. AM-CRM197 shows potential as an excellent candidate for a new carbohydrate-based vaccine that would be capable of eliciting a protective immune response against tuberculosis.
脂阿拉伯甘露聚糖（LAM）是[具体对象]的一种主要结构表面成分。本研究描述了明确的脂阿拉伯甘露聚糖（LAM）特异性十二糖-蛋白质缀合物的合成及免疫学研究。阿拉伯甘露聚糖（AM）十二糖已被高效合成并与载体蛋白共价缀合，包括交叉反应突变体（CRM197）白喉类毒素和牛血清白蛋白（BSA），以制备新型糖缀合物，从而构建一种有效的T细胞依赖性缀合疫苗。对该新型糖缀合物进行的初步小鼠免疫研究表明，在使用磷酸铝佐剂的情况下，4.0μg剂量的该缀合物可在小鼠体内产生较强的IgG抗体滴度。AM-CRM197显示出作为一种新型碳水化合物疫苗的优秀候选物的潜力，该疫苗能够引发针对结核病的保护性免疫反应。
Zotero 插件